<title>Abstract</title> Introduction: The Prostate Specific Membrane Antigen (PSMA) is a type II transmembrane glycoprotein known as Glutamate Carboxypeptidase II, overexpressed in prostate carcinoma. The Glu-Ureido moiety is a target-specific inhibitor for PSMA, and these widely used inhibitors show promising results in both non-invasive nuclear imaging and radionuclide-based therapeutic applications for prostate cancer. Materials and Methods In this study, 60 scaffolds based on Glu-Ureido-linked thiazolidinone-b…